This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by De Flora, S Articles by Carati, L Search for Related Content PubMed PubMed Citation Articles by De Flora, S Articles by Carati, L

Clinical Trial

Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment

N-acetylcysteine (NAC), an analogue and precursor of reduced glutathione, has been in clinical use for more than 30 yrs as a mucolytic drug. It has also been proposed for and/or used in the therapy and/or prevention of several respiratory diseases and of diseases involving an oxidative stress, in general. The objective of the present study was to evaluate the effect of long-term treatment with NAC on influenza and influenza-like episodes. A total of 262 subjects of both sexes (78% > or = 65 yrs, and 62% suffering from nonrespiratory chronic degenerative diseases) were enrolled in a randomized, double-blind trial involving 20 Italian Centres. They were randomized to receive either placebo or NAC tablets (600 mg) twice daily for 6 months. Patients suffering from chronic respiratory diseases were not eligible, to avoid possible confounding by an effect of NAC on respiratory symptoms. NAC treatment was well tolerated and resulted in a significant decrease in the frequency of influenza-like episodes, severity, and length of time confined to bed. Both local and systemic symptoms were sharply and significantly reduced in the NAC group. Frequency of seroconversion towards A/H1N1 Singapore 6/86 influenza virus was similar in the two groups, but only 25% of virus-infected subjects under NAC treatment developed a symptomatic form, versus 79% in the placebo group. Evaluation of cell-mediated immunity showed a progressive, significant shift from anergy to normoergy following NAC treatment. Administration of N-acetylcysteine during the winter, thus, appears to provide a significant attenuation of influenza and influenza-like episodes, especially in elderly high-risk individuals. N-acetylcysteine did not prevent A/H1N1 virus influenza infection but significantly reduced the incidence of clinically apparent disease.

This article has been cited by other articles:

				D. P. Arfsten, E. W. Johnson, A. R. Thitoff, A. E. Jung, E. R. Wilfong, S. M. Lohrke, T. A. Bausman, J. S. Eggers, and A. J. Bobb Impact of 30-Day Oral Dosing with N-acetyl-L-cysteine on Sprague-Dawley Rat Physiology International Journal of Toxicology, July 1, 2004; 23(4): 239 - 247. [Abstract] [Full Text] [PDF]

				P.N.R. Dekhuijzen Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease Eur. Respir. J., April 1, 2004; 23(4): 629 - 636. [Abstract] [Full Text] [PDF]

				F. J. Van Schooten, A. Besarati Nia, S. De Flora, F. D'Agostini, A. Izzotti, A. Camoirano, A. J. M. Balm, J. W. Dallinga, A. Bast, G. R. M. M. Haenen, et al. Effects of Oral Administration of N-Acetyl-L-cysteine: A Multi-Biomarker Study in Smokers Cancer Epidemiol. Biomarkers Prev., February 1, 2002; 11(2): 167 - 175. [Abstract] [Full Text] [PDF]

				S. De Flora, A. Izzotti, F. D'Agostini, and R. M. Balansky Mechanisms of N-acetylcysteine in the prevention of DNA damage and cancer, with special reference to smoking-related end-points Carcinogenesis, July 1, 2001; 22(7): 999 - 1013. [Abstract] [Full Text] [PDF]